Q-omics provides the consensus-scored ARL14EPP1 profile across patient tissues and cancer cell-line models. ARL14EPP1 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, ARL14EPP1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, ARL14EPP1 RNA expression shows 9,614 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, HNSC, and UVM as cancer lineages where ARL14EPP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARL14EPP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARL14EPP1 survival associations across molecular data types. ARL14EPP1 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARL14EPP1 RNA expression–survival associations across cancer types. High ARL14EPP1 expression shows unfavorable associations in UCEC, ACC, KIRC, MESO, SARC and SKCM. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for ARL14EPP1 RNA expression.
This table summarizes ARL14EPP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ARL14EPP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARL14EPP1 shows higher tumor expression in HNSC, BLCA, BRCA, LUSC, CHOL and STAD. The HNSC box plot shows higher ARL14EPP1 RNA expression in tumor versus normal tissue (log2 FC = +0.094, t-test p < 0.001).
This table shows molecular features associated with ARL14EPP1 in patient tissues and cancer cell lines. In patient samples, ARL14EPP1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
